Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

229 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Comparative effectiveness of glatiramer acetate and interferon beta formulations in relapsing-remitting multiple sclerosis.
Kalincik T, Jokubaitis V, Izquierdo G, Duquette P, Girard M, Grammond P, Lugaresi A, Oreja-Guevara C, Bergamaschi R, Hupperts R, Grand'Maison F, Pucci E, Van Pesch V, Boz C, Iuliano G, Fernandez-Bolanos R, Flechter S, Spitaleri D, Cristiano E, Verheul F, Lechner-Scott J, Amato MP, Cabrera-Gomez JA, Saladino ML, Slee M, Moore F, Gray O, Paine M, Barnett M, Havrdova E, Horakova D, Spelman T, Trojano M, Butzkueven H; MSBase Study Group. Kalincik T, et al. Mult Scler. 2015 Aug;21(9):1159-71. doi: 10.1177/1352458514559865. Epub 2014 Dec 5. Mult Scler. 2015. PMID: 25480857
Achieving patient engagement in multiple sclerosis: A perspective from the multiple sclerosis in the 21st Century Steering Group.
Rieckmann P, Boyko A, Centonze D, Elovaara I, Giovannoni G, Havrdová E, Hommes O, Kesselring J, Kobelt G, Langdon D, LeLorier J, Morrow SA, Oreja-Guevara C, Schippling S, Thalheim C, Thompson H, Vermersch P. Rieckmann P, et al. Mult Scler Relat Disord. 2015 May;4(3):202-18. doi: 10.1016/j.msard.2015.02.005. Epub 2015 Mar 2. Mult Scler Relat Disord. 2015. PMID: 26008937 Free article. Review.
The effect of oral immunomodulatory therapy on treatment uptake and persistence in multiple sclerosis.
Warrender-Sparkes M, Spelman T, Izquierdo G, Trojano M, Lugaresi A, Grand'Maison F, Havrdova E, Horakova D, Boz C, Oreja-Guevara C, Alroughani R, Iuliano G, Duquette P, Girard M, Terzi M, Hupperts R, Grammond P, Petersen T, Fernandez-Bolaños R, Fiol M, Pucci E, Lechner-Scott J, Verheul F, Cristiano E, Van Pesch V, Petkovska-Boskova T, Moore F, Kister I, Bergamaschi R, Saladino ML, Slee M, Barnett M, Amato MP, Shaw C, Shuey N, Young C, Gray O, Kappos L, Butzkueven H, Kalincik T, Jokubaitis V; MSBase study group. Warrender-Sparkes M, et al. Mult Scler. 2016 Apr;22(4):520-32. doi: 10.1177/1352458515594041. Epub 2015 Jul 21. Mult Scler. 2016. PMID: 26199347 Free article.
Increased albumin quotient (QAlb) in patients after first clinical event suggestive of multiple sclerosis is associated with development of brain atrophy and greater disability 48 months later.
Uher T, Horakova D, Tyblova M, Zeman D, Krasulova E, Mrazova K, Seidl Z, Vaneckova M, Krasensky J, Weinstock-Guttman B, Ramanathan M, Havrdova E, Zivadinov R. Uher T, et al. Mult Scler. 2016 May;22(6):770-81. doi: 10.1177/1352458515601903. Epub 2015 Sep 11. Mult Scler. 2016. PMID: 26362893 Clinical Trial.
229 results